Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses

A method for the treatment of pathologies or diseases associated to metabolic pathways involving the UBC13 enzyme or involving the transcriptional factor NF-κB, comprising administering to a patient a therapeutically effective amount of a compound of formula (I):

• R—(CR1R2)q—CO—N(R3)—C(R4R5)—CO—NH2
• wherein:
• R is the radical
• wherein:
• R6 is a radical selected from the group consisting of:
• H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted heterocyclylalkyl;
• A is a radical selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heterocyclyl;
• R7 and R8 are independently selected from H, methyl, ethyl, propyl and isopropyl,
• o is a number selected from the group consisting of 0, 1, 2, 3 and 4,
• n is a number selected from the group consisting of 0 and 1,
• the line — indicates the bonding site of the radical R with the rest of the molecule of formula (I);
• R1 and R2 are independently selected from the group consisting of H, methyl, ethyl, propyl and isopropyl;
• R3 is a radical selected from the group consisting of:
• H, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, and substituted or unsubstituted heterocyclylalkyl;
• R4 and R5 are independently selected from the group consisting of H, methyl, ethyl, propyl and isopropyl;
• and
• q is a number selected from the group consisting of 0 and 1;
• or a pharmaceutically acceptable salt or stereoisomer thereof.